Login / Signup

Reducing Mcl-1 gene dosage induces dopaminergic neuronal loss and motor impairments in Park2 knockout mice.

Susanna Ekholm-ReedRobert BakerAlexandre R CamposDavid StoufferMartha HenzeDieter A WolfJeanne F LoringElizabeth A ThomasSteven I Reed
Published in: Communications biology (2019)
Mutations in the PARK2 gene are associated with early onset Parkinsonism. The Park2 -/- mouse, however, does not exhibit neurodegeneration or other Parkinson's disease (PD) phenotypes. Previously, we discovered that translation of Mcl-1, a pro-survival factor, is upregulated in the Park2 -/- mouse, suggesting a compensatory mechanism during development. Here we generated the Park2 -/- Mcl-1 +/- mouse and show that by reducing Mcl-1 gene dosage by 50%, the Park2 -/- genotype is sensitized, conferring both dopaminergic neuron loss and motor impairments. We propose that this murine model could be a useful tool for dissecting PD etiology and developing treatment strategies against this neurodegenerative disease.
Keyphrases
  • early onset
  • genome wide
  • copy number
  • late onset
  • genome wide identification
  • dna methylation
  • gene expression
  • cerebral ischemia
  • genome wide analysis